Sign In / Join

close

Conferences

Our Conferences articles contain the latest coverage of medical advancements from recent academic conferences.

Headlines All Categories Treatment Advances Navigating Your Health Core Education Patient Stories HealthTree Research Conferences Clinical Trials HealthTree Programs HealthTree Press

Recent Articles

Breaking Potential New Standard of Care for Relapsed/Refractory Follicular Lymphoma Patients

December 17, 2024

Discover how adding tafasitamab to lenalidomide + rituximab improves outcomes for relapsed/refractory follicular lymphoma patients.

Bendamustine Before CAR T-cell Therapy Shows Lower Side Effects While Maintaining Efficacy

December 17, 2024

ASH 2024: bendamustine lymphodepletion before CAR T-cell therapy in aggressive lymphomas leads to fewer side effects while maintaining survival benefits.

The Best of ASH 2024

December 10, 2024

Discover the board's selection of best abstracts at the 66th annual ASH conference.

Effects of Eating Fiber, Plant-Based Diet, Keto Diet, and Smoking on Certain Blood Cancers

December 10, 2024

Read research highlights from the ASH 2024 conference how certain lifestyle choices affect blood cancers.

What Research is Being Discussed for DLBCL at ASH 2024?

December 08, 2024

Read about some of today’s DLBCL research topics presented at the ASH 2024 conference.

Follicular Lymphoma Specialists Share Insights on New Treatments

December 07, 2024

Learn about new treatments and recommendations to current therapies from follicular lymphoma specialists speaking at the 2024 ASH conference.

What is the ASH Conference?

December 02, 2024

The American Society of Hematology's annual conference is a significant event for the blood cancer community, including those involved in DLBCL research.

What is the ASH Conference?

December 02, 2024

The American Society of Hematology's annual conference is a significant event for the blood cancer community, including those involved in FL research.

Real-world Results for Preventing Infections in CLL and Non-Hodgkin Lymphoma Patients

November 15, 2024

New study shows IVIG replacement lowers infection risk in CLL and NHL patients, highlighting the need for better IgG testing and IgRT guidelines.

Is it Safe for R/R DLBCL Patients to Receive CAR T-cell Therapy in an Outpatient Setting?

October 22, 2024

Is it safe for relapsed/refractory non-Hodgkin lymphoma patients, including DLBCL, to receive CAR T-cell therapy in an outpatient setting?

Charity Navigator

HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.

Tax ID 45-5354811

Conferences

Recent Articles

Breaking Potential New Standard of Care for Relapsed/Refractory Follicular Lymphoma Patients

Bendamustine Before CAR T-cell Therapy Shows Lower Side Effects While Maintaining Efficacy

The Best of ASH 2024

Effects of Eating Fiber, Plant-Based Diet, Keto Diet, and Smoking on Certain Blood Cancers

What Research is Being Discussed for DLBCL at ASH 2024?

Follicular Lymphoma Specialists Share Insights on New Treatments

What is the ASH Conference?

What is the ASH Conference?

Real-world Results for Preventing Infections in CLL and Non-Hodgkin Lymphoma Patients

Is it Safe for R/R DLBCL Patients to Receive CAR T-cell Therapy in an Outpatient Setting?

Get the latest thought leadership on your Non-Hodgkin Lymphoma delivered straight to your inbox

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info